A new group of drugs called enzalutamide for people with advanced prostate cancer has shown a steady increase in survival rates of 67% after 5 years.
The treatment, developed by a research group under the supervision of the Director of the Cancer Immunology Institute at the University of South Australia, Dr. Christopher Sweeney, depends on suppressing testosterone, with or without chemotherapy.
The study's trials were published in the journal "The Lancet Oncology", and the survival rate after receiving the new treatment is 67%, while the rate with the standard treatment currently used is 57%.
"Long-term analysis showed that the benefit of adding enzalutamide was evident in all subgroups of patients, regardless of when the cancer spread, how far it had spread, or whether people also received docetaxel chemotherapy," Dr. Sweeney said.
He added: “These high-level results indicate that the addition of enzalutamide should be considered as a treatment option for any patient who is able to receive it. And that it may not be necessary to add other treatments such as chemotherapy, ”according to 24ae.
Okaz (Melbourne) @OKAZ_online
